Kestra Medical Technologies (KMTS) EBITDA (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of EBITDA data on file, last reported at -$39.3 million in Q2 2026.

• On a quarterly basis, EBITDA rose 18.39% year-over-year to -$39.3 million in Q2 2026; TTM through Apr 2026 was -$134.7 million, a 26.66% decrease from a year earlier, with the FY2026 full-year figure at -$134.7 million, down 26.66% from the prior year.
• EBITDA for Q2 2026 stood at -$39.3 million, down from -$34.8 million in the prior quarter.
• Over the last five years, EBITDA for KMTS reached as high as -$18.4 million in Q3 2024 and fell as low as -$48.2 million in Q2 2025.
• Historically, EBITDA has averaged -$28.1 million across 3 years, with a median of -$24.7 million in 2025.
• Across the five-year window, EBITDA sank 136.93% in 2025 and rose 18.39% in 2026, its largest moves.
• Year by year, EBITDA stood at -$19.1 million in 2024, then slumped by 65.96% to -$31.8 million in 2025, then fell by 23.9% to -$39.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$39.3 million in Q2 2026, -$34.8 million in Q1 2026, and -$31.8 million in Q4 2025.